During the past decade, Marien Hospital Düsseldorf conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 12 clinical trials were completed, i.e. on average, 46.2% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 10 clinical trials were completed. i.e. 166.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Marien Hospital Düsseldorf" #1 sponsor was "Celgene" with 8 trials, followed by "Astex Pharmaceuticals, Inc." with 2 trials sponsored, "GWT-TUD GmbH" with 2 trials sponsored, "German CLL Study Group" with 2 trials sponsored and "Prof. Dr. M. Dreyling (co-chairman)" with 2 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Marien Hospital Düsseldorf" #1 collaborator was "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 2 trials as a collaborator, "Amsterdam UMC, location VUmc" with 2 trials as a collaborator, "Groupe Francophone des Myelodysplasies" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator and "AstraZeneca" with 1 trials as a collaborator. Other collaborators include 21 different institutions and companies that were collaborators in the rest 31 trials.

According to Clinical.Site data, the most researched conditions in "Marien Hospital Düsseldorf" are "Acute Myeloid Leukemia" (7 trials), "Myelodysplastic Syndromes" (7 trials), "Myelodysplastic Syndrome" (5 trials), "Leukemia, Myeloid, Acute" (3 trials) and "Leukemia, Myelomonocytic, Chronic" (3 trials). Many other conditions were trialed in "Marien Hospital Düsseldorf" in a lesser frequency.

Most popular intervention types in "Marien Hospital Düsseldorf" are "Drug" (33 trials), "Other" (6 trials), "Biological" (3 trials), "Procedure" (2 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Lenalidomide" (4 trials), "Azacitidine" (3 trials), "Luspatercept" (3 trials) and "Obinutuzumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Marien Hospital Düsseldorf" are 34 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Marien Hospital Düsseldorf". 1 are not yet recruiting, 6 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Marien Hospital Düsseldorf, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Marien Hospital Düsseldorf, 0 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 22 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

Marien Hospital Düsseldorf has several departments that took part in Clinical trials: "Marien Hospital Dusseldorf GmbH, Klinik Fur Onkologie, Hamatologie Und Palliativmedizin" - 2 trials